Risk stratification in cardiomyopathies (dilated, hypertrophic, and arrhythmogenic cardiomyopathy) by cardiac magnetic resonance imaging
- PMID: 34650369
- PMCID: PMC8503531
- DOI: 10.1093/eurheartj/suab105
Risk stratification in cardiomyopathies (dilated, hypertrophic, and arrhythmogenic cardiomyopathy) by cardiac magnetic resonance imaging
Abstract
Cardiac magnetic resonance imaging (CMR) is a non-invasive, multiplanar, and high spatial resolution imaging technique, which represents the current gold standard for the evaluation of biventricular volumes and function. Furthermore, unlike other methods, it has the great advantage of characterizing the myocardial tissue by identifying the presence of alterations, such as oedema and focal and diffuse fibrosis. In particular, the late gadolinium enhancement technique makes it possible to identify areas of focal fibrosis that often constitute the substrate for the triggering of threatening ventricular arrhythmias at the basis of sudden cardiac death. For this reason, the use of CMR in the study of cardiomyopathies has become of primary importance, both for the differential diagnosis and for patient risk stratification. In this brief review, the ability of CMR in prognostic stratification of patients with dilated, hypertrophic, and arrhythmogenic cardiomyopathy will be analysed. In particular, the role of CMR in the prediction of arrhythmic risk and in the decision-making process for the implantation of a cardiac defibrillator will be examined.
Keywords: Arrhythmic risk; Cardiac magnetic resonance; Implantable cardiac-defibrillator.
Published on behalf of the European Society of Cardiology. © The Author(s) 2021.
Figures
References
-
- Pontone G, Guaricci AI, Andreini D, Solbiati A, Guglielmo M, Mushtaq S, Baggiano A, Beltrama V, Fusini L, Rota C, Segurini C, Conte E, Gripari P, Dello Russo A, Moltrasio M, Tundo F, Lombardi F, Muscogiuri G, Lorenzoni V, Tondo C, Agostoni P, Bartorelli AL, Pepi M.. Prognostic benefit of cardiac magnetic resonance over transthoracic echocardiography for the assessment of ischemic and nonischemic dilated cardiomyopathy patients referred for the evaluation of primary prevention implantable cardioverter-defibrillator therapy. Circ Cardiovasc Imaging 2016;9:e004956. - PubMed
-
- Castelli G, Fornaro A, Ciaccheri M, Dolara A, Troiani V, Tomberli B, Olivotto I, Gensini GF.. Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management. Circ Heart Fail 2013;6:913–921. - PubMed
-
- Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221–1230. - PubMed
-
- Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck K-H, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ; ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793–2867. - PubMed